Updated:
Janux Therapeutics
Janux Therapeutics was founded in 2017 and is headquartered in San Diego, California, with David Campbell serving as President and CEO.
Janux Therapeutics
Janux Therapeutics was founded in 2017 and is headquartered in San Diego, California, with David Campbell serving as President and CEO. The company emerged from the surrounding life-sciences ecosystem to address a persistent challenge in oncology: the on-target, off-tumor toxicity that limits the effectiveness of T-cell engager therapies. Rather than scaling a family fortune, Janux was built on institutional and public-market capital, completing its initial public offering on Nasdaq in June 2021 (per Janux Therapeutics, 2021). The firm's strategy centers on its proprietary Tumor Activated T Cell Engager, or TRACTr, platform, which engineers bispecific antibodies that remain inert in healthy tissue. The therapeutic candidates target validated oncology antigens — including PSMA, EGFR, and TROP2 — across solid tumor indications such as prostate, colorectal, and non-small cell lung cancer. Asset classes are confined to biotechnology R&D, with capital deployed predominantly into preclinical and Phase 1 clinical programs. Confirmed pipeline assets include JANX007 for metastatic castration-resistant prostate cancer and JANX008 targeting EGFR-expressing tumors. The geographic footprint spans US-based operations, though clinical trial sites extend to multiple geographies within North America per federal trial registrations. Janux disclosed approximately $341 million in cash and cash equivalents at the end of 2024 (per the firm's 2024 10-K filing), positioning it to fund operations into 2028. The company's leadership team includes Tighe Reardon as SVP of Finance and Administration, but a precise employee count has not been publicly disclosed. In October 2024, Janux reported early clinical safety data for JANX007 that showed encouraging activity at higher doses without dose-limiting toxicities (per Janux Therapeutics, October 2024). There are no adjacent vehicles, philanthropic foundations, or club memberships that form part of the firm's public architecture. The structural differentiator lies in Janux's conditional-activation mechanism, which chemically masks the binding domain of its antibodies using a peptide cloak that is cleaved only by proteases overexpressed in the tumor microenvironment. This is a specific molecular design choice — not a general immunotherapy claim — that separates the firm from peers pursuing fixed dosing in the T-cell engager space, and it represents a clear technical wager on the pharmacokinetics of tumor-localized activation over systemic exposure.
General information
Firm type
Asset Manager
Year founded
2017
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Principals
David Campbell
President and Chief Executive Officer
Andy Meyer
Chief Business Officer
Tighe Reardon
Senior Vice President, Finance and Administration
Sector focus
Frequently asked questions
What is Janux Therapeutics' core scientific platform?
Janux's core asset is the TRACTr platform, which produces bispecific T-cell engager antibodies that are masked by a proprietary peptide sequence. The mask is designed to be cleaved by specific proteases enriched in the tumor microenvironment, limiting systemic immune activation. The company's pipeline centers on prostate cancer (JANX007) and EGFR-positive solid tumors (JANX008). (per Janux Therapeutics corporate overview, 2024)
How does Janux fund its operations?
Janux is a publicly traded Biotech listed on Nasdaq under the ticker JANX. It completed its initial public offering in June 2021, raising $150 million in gross proceeds. The firm has no private capital or single-family-office backing, relying on periodic public equity offerings and, as of year-end 2024, reported $341 million in cash reserves. (per Janux Therapeutics S-1 and 10-K filings)
Does Janux have clinical data in patients?
Yes, Janux is conducting Phase 1/1a clinical trials for both lead candidates. In October 2024, the company disclosed that JANX007 had generated objective responses in patients with advanced metastatic prostate cancer at higher dose levels, with a safety profile that avoided the dose-limiting toxicities common to first-generation T-cell engagers. (per Janux Therapeutics press release, October 2024)
How is Janux different from other T-cell engager biotech companies?
The critical difference is the conditional activation mechanism. Many T-cell engagers bind tumor antigens regardless of location, creating severe off-tumor toxicity in organs that express even low levels of the target. Janux's design keeps the antibody inactive until a tumor-specific protease trims the mask. This is a structural solution to the therapeutic window problem, not simply a different antigen choice or affinity tuning.
Who handles investment decisions at Janux?
As a public operating company developing biologic drugs, Janux does not have a chief investment officer. Allocation of the firm's cash balance into short-term instruments is managed by its financial administration leadership under Tighe Reardon. Strategic prioritization — which programs receive development capital — is the purview of CEO David Campbell and the board of directors.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: